Abstract
Background: Several risk factors have been empirically linked to an increased risk of cardiovascular disease. Some of them are therapeutically amenable to modification; while others are not. Modifiable risk factors include physical inactivity, tobacco use, diet, “bad fats” in the blood, hypertension, and being overweight; while non-modifiable risk factors include the patient’s family history, the presence versus absence of diabetes mellitus, and demographic characteristics like age, gender, ethnicity, and socio-economic status.
Methods: In this article, we review those risk factors that are both clinically important and amenable to change.
Conclusion: To prevent cardiovascular disease, it is important to minimize modifiable risk factors, like LDL cholesterol.
Keywords: Cardiovascular disease, coronary heart disease, diabetes, high blood pressure, hypertension, ischemic heart disease, LDL cholesterol.
Graphical Abstract
[1]
Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499.
[2]
Cohen JC. Sequence variations in PCSK9, low LDL and protection against coronary heart disease. N Engl J Med 2006; 354: 1264.
[3]
Cholesterol Treatment Trialists’ Collaboration Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
[4]
Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: Results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535-45.
[5]
Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA 2013; 310: 2451-2.
[6]
Ginsberg HN, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
[7]
Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99.
[8]
Piepoli M. Hoes Aw, Agewall S, et al European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37(29): 2315-81.
[9]
AIM-HIGH Investigators, Boden WE, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
[10]
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
[11]
Bansal S, Buring JE, Rifai N, et al. Fasting compared with non fasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-16.
[12]
Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-53.
[13]
Jhia P, Ramasundarahettige C, Landsman V, et al. 21st century hazards of smoking and benefits of cessation in United States. N Engl J Med 2013; 368: 341.
[14]
Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: Longitudinal population study. BMJ 1998; 316: 1043-7.
[15]
Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: An evaluation of the evidence. BMJ 1997; 315: 973-80.
[16]
Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11CD000146
[17]
Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies. A network meta-analysis. Circulation 2014; 129(1): 28-41.
[18]
Pasceri V. Homocysteine and coronary heart disease: A review of the current evidence. Semin Interv Cardiol 1999; 4: 121.
[19]
Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2015; 1CD006612
[20]
Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up on participants of Framingham Heart Study. Circulation 1983; 67: 968-77.
[21]
Berrington de Gonzalez A, Hartge P, Cerhan JR. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211-9.
[23]
Britton KA, Massaro JM, Murabito JM, et al. Body fat distribution, incidence cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol 2013; 62: 921-5.
[24]
Jensen MD, Ryan DH, Apovian CM, et al. AHA/ACC/TOS Guideline for the management of overweight and obesity in adults: A report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. J Am Coll Cardiol 2013; (13): S0735.
[25]
Shiroma EJ, Lee IM. Physical activity and cardiovascular health: Lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 2010; 122: 743.
[26]
Leon AS, Connett J. Physical activity and 10.5 year mortality in the multiple risk factors intervention trial. Int J Epidemiol 1991; 20: 690-7.
[27]
U.S. Department of Health and Human Services: 2008 physical activity guidelines for Americans. Available a. http://www.health.gov/paguidelines/pdf/paguide
[28]
Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: A meta-analysis. Circulation 2011; 124: 789.
[29]
Eaker ED, Abbott RD, Kannel WB. Frequency of uncomplicated angina pectoris in type A compared with type B persons (the Framingham Study). Am J Cardiol 1989; 63: 1042.
[30]
Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 1994; 90: 2225-9.
[31]
Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-80.
[32]
Zen AL, Whooley MA, Zhao S, Cohen BE. Post-traumatic stress disorder is associated with poor health behaviors: Findings from the heart and soul study. Health Psychol 2012; 31: 194-201.
[33]
Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-52.
[34]
Libby P, Hansson GK. Inflammation and immunity in diseases of the arterial tree: Players and layers. Circ Res 2015; 116: 307-11.
[36]
de Beer FC, Hind CR, Fox KM, et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 1982; 47: 239-43.
[37]
Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
[38]
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
[39]
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
[40]
Emerging Risk Factors Collaboration, Kaptoge S, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310.
[41]
Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
[42]
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-56.
[43]
Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39: 809-21.
[44]
Friedman GD, Selby JV, Quesenberry CP Jr, Armstrong MA, Klatsky AL. Precursors of essential hypertension: Body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988; 17: 387-402.
[46]
Fagard R, Brguljan J, Staessen J, et al. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension 1995; 26: 919-24.
[47]
Reichek N, Devereux RB. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981; 63: 1391-8.
[48]
Tsioufis C, Kokkinos P, Macmanus C, et al. Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. J Hypertens 2010; 28: 2299-308.
[49]
Cuspidi C, Ambrosioni E, Mancia G, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: The assessment of prognostic risk observational survey. J Hypertens 2002; 20: 1307-14.
[50]
Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
[51]
Codella NC, Lee HY, Fieno DS, et al. Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm. Circ Cardiovasc Imaging 2012; 5: 137-46.
[52]
Parsai C, O’Hanlon R, Prasad SK, Mohiaddin RH. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012; 14: 54.
[53]
Groppelli A, Omboni S, Parati G, Mancia G. Blood pressure and heart rate response to repeated smoking before and after beta-blockade and selective alpha 1 inhibition. J Hypertens 1990; 8(Suppl. 5): S35-40.
[54]
Mann SJ, James GD, Wang RS, Pickering TG. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. JAMA 1991; 265: 2226-8.
[55]
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
[56]
Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012; 60: 1271-7.
[57]
WHO Consultation Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus Geneva: World Health Organization; 1999 Report no 992 Available at: http://whqlibdoc.who.int/hq/ 1999/who_ncd_ncs_99.2.pdf
[58]
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl. 1): S64-71.
[59]
Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients. Diabetes Care 1993; 16: 902-10.
[60]
Tuomilehto J, Zimmet P, Mackay IR, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994; 343: 1383-5.
[61]
DIAMOND Project Group. Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet Med 2006; 23: 857-66.
[62]
Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3-19.
[63]
Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. Lancet 2012; 380: 601.
[64]
Orchard TJ. The impact of gender and general risk factors on the occurrence of atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 323-33.
[65]
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-96.
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
Article Metrics
73
6